0000000000822481

AUTHOR

Stefania Tringali

showing 2 related works from this author

Complete Clinical Remission after High-Dose Immune Suppression and Autologous Hematopoietic Stem Cell Transplantation in Severe Crohn’s Disease Refra…

2004

Crohn's diseaseautologous hematopoieticbusiness.industrymedicine.medical_treatmentGastroenterologyHematopoietic stem cell transplantationmedicine.diseasearthritiImmune systemRefractoryMultiple SclerosiImmunologyautologous hematopoietic stem cell transplantationmedicineImmunology and AllergyarthralgiabusinessInflammatory Bowel Diseases
researchProduct

Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective …

2018

Abstract Background: Triplet-based lenalidomide plus dexamethasone (Rd) combinations have become the new standard of care for early relapse and refractory multiple myeloma (RRMM). Carfilzomib is a novel selective proteasome inhibitor (PI) with high efficacy in RRMM. The ASPIRE phase 3 trial showed the superiority of carfilzomib-based triplet (KRd compared to Rd), leading to approval of K for RRMM. However, little is known about safety and efficacy of KRd outside a clinical trial context. Experimental design and aims: In 11 Sicilian Centers belonging to the Sicilian Myeloma Network, from November 2016, when KRd regimen was approved in Italy, to June 2018, 103 consecutive RRMM patients (previ…

medicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiescomplete remissionImmunologylenalidomideadverse eventContext (language use)dexamethasoneBiochemistrychemistry.chemical_compoundMedian follow-upInternal medicinemedicinecarfilzomib dexamethasone lenalidomide multiple myeloma toxic effect adverse event bortezomib complete remission erythropoietin febrile neutropeniaMultiple myelomaLenalidomidetoxic effectcarfilzomibbusiness.industryCumulative dosebortezomibCell BiologyHematologymedicine.diseaseCarfilzomibmultiple myelomaRegimenfebrile neutropeniachemistryerythropoietinbusinessFebrile neutropeniamedicine.drug
researchProduct